Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study-Reference-Cited by-同舟云学术

Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

Published:2017-12 Issue:1 Volume:17 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Tanaka Yosuke,Hino Mitsunori,Gemma Akihiko

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12890-017-0523-2.pdf

Reference36 articles.

1. Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéry JL. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62:D109–16.

2. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, Mishima M, Kitaichi M, Izumi T. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007;131:650–6.

3. Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, Sakamoto K, Hasegawa Y. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration. 2013;85:456–63.

4. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31:1357–67.

5. Minai OA, Santacruz JF, Alster JM, Budev MM, McCarthy K. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med. 2012;106:1613–21.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention—prospective, single-center, randomized, parallel-group study;BMC Pulmonary Medicine;2024-02-17

2. Improvement in idiopathic interstitial pneumonia by adding macitentan to a patient unresponsive to nintedanib;Respiratory Medicine Case Reports;2024

3. Pharmacoeconomic justification of the choice of specific therapy schemes for the treatment of adult patients with pulmonary arterial hypertension;Farmatsevtychnyi zhurnal;2022-08-29

4. Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis;Frontiers in Pharmacology;2022-06-03

5. Endothelin receptor antagonists for pulmonary arterial hypertension;Cochrane Database of Systematic Reviews;2021-03-25